Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction

P. J. Schilling, J. L. Murray, Avi Markowitz

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Recombinant human tumor necrosis factor is an investigational antitumor agent currently undergoing clinical trials. Previous reports of pulmonary and hepatic toxicities include mild reversible decline in pulmonary diffusing capacity and mild elevation of bilirubin and transaminases. This report describes two novel toxicities in patients receiving their first intravenous dose of tumor necrosis factor: pulmonary hemorrhage and severe hepatic dysfunction. These patients received no other antitumor therapy for at least 4 weeks before tumor necrosis factor treatment and no additional antitumor therapy concomitant with tumor necrosis factor. An analysis of the possible pathogenesis is presented.

    Original languageEnglish (US)
    Pages (from-to)256-260
    Number of pages5
    JournalCancer
    Volume69
    Issue number1
    StatePublished - 1992

    Fingerprint

    Poisons
    Tumor Necrosis Factor-alpha
    Hemorrhage
    Lung
    Liver
    Pulmonary Diffusing Capacity
    Transaminases
    Bilirubin
    Antineoplastic Agents
    Therapeutics
    Clinical Trials

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Schilling, P. J., Murray, J. L., & Markowitz, A. (1992). Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction. Cancer, 69(1), 256-260.

    Novel tumor necrosis factor toxic effects : Pulmonary hemorrhage and severe hepatic dysfunction. / Schilling, P. J.; Murray, J. L.; Markowitz, Avi.

    In: Cancer, Vol. 69, No. 1, 1992, p. 256-260.

    Research output: Contribution to journalArticle

    Schilling, PJ, Murray, JL & Markowitz, A 1992, 'Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction', Cancer, vol. 69, no. 1, pp. 256-260.
    Schilling, P. J. ; Murray, J. L. ; Markowitz, Avi. / Novel tumor necrosis factor toxic effects : Pulmonary hemorrhage and severe hepatic dysfunction. In: Cancer. 1992 ; Vol. 69, No. 1. pp. 256-260.
    @article{738dbcf5a59c450a8d56a5b4b8820262,
    title = "Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction",
    abstract = "Recombinant human tumor necrosis factor is an investigational antitumor agent currently undergoing clinical trials. Previous reports of pulmonary and hepatic toxicities include mild reversible decline in pulmonary diffusing capacity and mild elevation of bilirubin and transaminases. This report describes two novel toxicities in patients receiving their first intravenous dose of tumor necrosis factor: pulmonary hemorrhage and severe hepatic dysfunction. These patients received no other antitumor therapy for at least 4 weeks before tumor necrosis factor treatment and no additional antitumor therapy concomitant with tumor necrosis factor. An analysis of the possible pathogenesis is presented.",
    author = "Schilling, {P. J.} and Murray, {J. L.} and Avi Markowitz",
    year = "1992",
    language = "English (US)",
    volume = "69",
    pages = "256--260",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Novel tumor necrosis factor toxic effects

    T2 - Pulmonary hemorrhage and severe hepatic dysfunction

    AU - Schilling, P. J.

    AU - Murray, J. L.

    AU - Markowitz, Avi

    PY - 1992

    Y1 - 1992

    N2 - Recombinant human tumor necrosis factor is an investigational antitumor agent currently undergoing clinical trials. Previous reports of pulmonary and hepatic toxicities include mild reversible decline in pulmonary diffusing capacity and mild elevation of bilirubin and transaminases. This report describes two novel toxicities in patients receiving their first intravenous dose of tumor necrosis factor: pulmonary hemorrhage and severe hepatic dysfunction. These patients received no other antitumor therapy for at least 4 weeks before tumor necrosis factor treatment and no additional antitumor therapy concomitant with tumor necrosis factor. An analysis of the possible pathogenesis is presented.

    AB - Recombinant human tumor necrosis factor is an investigational antitumor agent currently undergoing clinical trials. Previous reports of pulmonary and hepatic toxicities include mild reversible decline in pulmonary diffusing capacity and mild elevation of bilirubin and transaminases. This report describes two novel toxicities in patients receiving their first intravenous dose of tumor necrosis factor: pulmonary hemorrhage and severe hepatic dysfunction. These patients received no other antitumor therapy for at least 4 weeks before tumor necrosis factor treatment and no additional antitumor therapy concomitant with tumor necrosis factor. An analysis of the possible pathogenesis is presented.

    UR - http://www.scopus.com/inward/record.url?scp=0026499946&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0026499946&partnerID=8YFLogxK

    M3 - Article

    C2 - 1309306

    AN - SCOPUS:0026499946

    VL - 69

    SP - 256

    EP - 260

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 1

    ER -